RECOVERY & TISSUE REPAIR
The Signaling Behind Healing
Three peptides studied for how tissue tells itself to repair — a copper-carrying tripeptide, an anti-inflammatory gut-and-skin fragment, and a heavily marketed actin-binding heptapeptide with more reputation than confirmed human data.
GHK-Cu
A copper-binding tripeptide that occurs naturally inside collagen, studied for decades in dermal fibroblast signaling — the deepest human evidence on this desk, and still confirmed only in topical form.
View →KPV
An anti-inflammatory fragment of alpha-MSH that keeps the parent hormone's calming effect without its pigment-darkening one — studied entirely in cells and mice, with no completed human trials.
View →TB-500
The commercial name for a seven-amino-acid fragment of Thymosin Beta-4 — the compound that draws the most questions on this desk, and about which the least is directly confirmed.
View →The short version
When skin, a tendon, or a gut lining gets hurt, cells don't just clot and wait — they send chemical messages that tell nearby cells to migrate, multiply, and rebuild. Some of the smallest of those messages are peptides: short chains of amino acids, the same building blocks that make up every protein, only far shorter and simpler.
This site follows three peptides that show up again and again in the tissue-repair research literature: GHK-Cu, a copper-carrying fragment that occurs naturally inside collagen and switches on skin- and wound-repair genes; KPV, a tiny anti-inflammatory piece of a hormone the pituitary gland already makes, best studied for calming an inflamed gut lining; and TB-500, the commercial name given to a fragment of a protein platelets release at every injury site — and the one compound here with the widest gap between its reputation and its confirmed human evidence.
We report what was studied, in what species, under what conditions — and just as importantly, what wasn't. Nothing on this site is a recommendation to take anything, at any dose.
The signaling behind healing
Healing is not one event; it is a sequence of overlapping signals, and each peptide on this desk sits at a different point in that sequence. GHK-Cu works closest to the finished product: it is released as collagen itself breaks down, and in fibroblasts — the cells that lay down new collagen and elastin — it switches on a broad program of matrix-building and antioxidant genes, altering expression of roughly 31% of measured genes at a 50%-or-greater change threshold [2]. KPV works earlier and more narrowly, at the inflammatory phase: it is a fragment of alpha-melanocyte-stimulating hormone that suppresses the NF-kB and MAP-kinase signaling driving tissue damage, without the pigment-darkening effect the full hormone carries, and gut epithelial cells actively transport it in through a specialized channel called PepT1 that is upregulated wherever tissue is inflamed [10]. TB-500 sits at the mobilization step: the full-length protein it is named for buffers a cellular building block called actin, freeing repair cells to migrate toward an injury and encouraging new blood-vessel growth [15][17].
The three don't compete for the same job — they describe three different signals a healing tissue sends. But they carry very different amounts of confirmed evidence behind them, and that gap is one of the through-lines of this site: GHK-Cu has small human trials, KPV has none, and TB-500's commercial form has almost none of its own, borrowing evidence from a larger relative it may or may not fully resemble.
What are research peptides?
"Research peptide" is a supply-chain label, not a medical one. It describes material sold by chemical suppliers for laboratory use, with no guarantee of the purity, sterility, or identity a pharmaceutical product carries, and — for two of the three compounds here — no approved human use of any kind. GHK-Cu is the exception in one narrow sense: Copper Tripeptide-1, its cosmetic-ingredient name, is a legal, widely sold topical skincare additive in the US, EU, and UK, with a long safety record in that specific form. Injecting or otherwise taking any of the three compounds into the body is unapproved, unregulated, and not something this site describes, recommends, or facilitates.
Because the underlying research spans human clinical trials, mouse and rat models, and cell-culture work, the strength of evidence varies enormously by compound and by claim — a lab dish finding and a 40-person human safety trial are not the same kind of evidence, and this site is careful to say which is which every time. Where a finding was measured in a specific species, at a specific dose, in a specific model, that context is kept intact rather than smoothed into a general claim.